Citations

Showing 10 of 108152 citations.

2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis
Maz, Mehrdad , Abril, Andy , Langford, Carol A. , Gorelik, Mark , Archer, Amy M., Conn, Doyt L. , Full, Kathy A., Grayson, Peter C. , Ibarra, Maria, Imundo, Lisa F., Kim, Susan , Rhee, Rennie L. , Stone, John H. , Sule, Sangeeta , Vitobaldi, Omar I., Warner, Ann, Byram, Kevin , Dua, Anisha B. , Husainat, Nedaa , Kalot, Mohamad A. , Lin, Yih Chang, Springer, Jason , Turgunbaev, Marat, Villa‐Forte, Alexandra, Turner, Amy S. , Conn, Doyt L , Grayson, Peter C , Merkel, Peter A , Rhee, Rennie L , Stone, John H , Sule, Sangeeta , Husainat, Nedaa M , Kalot, Mohamad A , Springer, Jason M , Turner, Amy S , Mustafa, Reem A , Maz, Mehrdad , Dua, Anisha B , Chung, Sharon A. , Guyatt, Gordon , Merkel, Peter A. , Seo, Philip , Sundel, Robert P. , Warner, Ann, James, Karen E.

Mayo Clinic

Arthritis Care & Research | July 8, 2021 | Volume: 73 | Issue: 8 | Pages: 1071-1087

10.1002/acr.24632 | PMID 34235871 Get It

Objective To provide evidence‐based recommendations and expert guidance for the management of giant cell arteritis (GCA) and Takayasu arteritis (TAK) as exemplars of large vessel vasculitis. Methods Clinical questions regarding diagnostic testing, treatment, and management were developed in the population, intervention, comparator, and outcome (PICO) format for GCA and TAK (27 for GCA, 27 for TAK). Systematic literature reviews were conducted for each PICO question. The Grading of Recommendations Assessment, Development and Evaluation methodology was used to rate the quality of the evidence. Recommendations were developed by the Voting Panel, comprising adult and pediatric rheumatologists and patients. Each recommendation required ≥70% consensus among the Voting Panel. Results We present 22 recommendations and 2 ungraded position statements for GCA, and 20 recommendations and 1 ungraded position statement for TAK. These recommendations and statements address clinical questions relating to the use of diagnostic testing, including imaging, treatments, and surgical interventions in GCA and TAK. Recommendations for GCA include support for the use of glucocorticoid‐sparing immunosuppressive agents and the use of imaging to identify large vessel involvement. Recommendations for TAK include the use of nonglucocorticoid immunosuppressive agents with glucocorticoids as initial therapy. There were only 2 strong recommendations; the remaining recommendations were conditional due to the low quality of evidence available for most PICO questions. Conclusion These recommendations provide guidance regarding the evaluation and management of patients with GCA and TAK, including diagnostic strategies, use of pharmacologic agents, and surgical interventions.
2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Polyarteritis Nodosa
Gorelik, Mark , Langford, Carol A. , Maz, Mehrdad , Abril, Andy , Archer, Amy M., Conn, Doyt L. , Full, Kathy A., Grayson, Peter C. , Ibarra, Maria, Imundo, Lisa F., Kim, Susan , Rhee, Rennie L. , Stone, John H. , Sule, Sangeeta , Vitobaldi, Omar I., Warner, Ann, Byram, Kevin , Husainat, Nedaa , Kalot, Mohamad A. , Lin, Yih Chang, Springer, Jason , Turgunbaev, Marat, Villa‐Forte, Alexandra, Turner, Amy S. , Maz, Mehrdad , Conn, Doyt L , Grayson, Peter C , Merkel, Peter A , Rhee, Rennie L , Stone, John H , Sule, Sangeeta , Husainat, Nedaa M , Kalot, Mohamad A , Springer, Jason M , Turner, Amy S , Mustafa, Reem A , Chung, Sharon A. , Guyatt, Gordon , Merkel, Peter A. , Seo, Philip , Sundel, Robert P. , Warner, Ann, Dua, Anisha B. , James, Karen E.

Mayo Clinic

Arthritis & Rheumatology | July 8, 2021 | Volume: 73 | Issue: 8 | Pages: 1384-1393

10.1002/art.41776 | PMID 34235883 Get It

Objective To provide evidence‐based recommendations and expert guidance for the management of systemic polyarteritis nodosa (PAN). Methods Twenty‐one clinical questions regarding diagnostic testing, treatment, and management were developed in the population, intervention, comparator, and outcome (PICO) format for systemic, non–hepatitis B–related PAN. Systematic literature reviews were conducted for each PICO question. The Grading of Recommendations Assessment, Development and Evaluation methodology was used to assess the quality of evidence and formulate recommendations. Each recommendation required ≥70% consensus among the Voting Panel. Results We present 16 recommendations and 1 ungraded position statement for PAN. Most recommendations were graded as conditional due to the paucity of evidence. These recommendations support early treatment of severe PAN with cyclophosphamide and glucocorticoids, limiting toxicity through minimizing long‐term exposure to both treatments, and the use of imaging and tissue biopsy for disease diagnosis. These recommendations endorse minimizing risk to the patient by using established therapy at disease onset and identify new areas where adjunctive therapy may be warranted. Conclusion These recommendations provide guidance regarding diagnostic strategies, use of pharmacologic agents, and imaging for patients with PAN.
2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
Langford, Carol A. , Maz, Mehrdad , Abril, Andy , Gorelik, Mark , Archer, Amy M., Conn, Doyt L. , Full, Kathy A., Grayson, Peter C. , Ibarra, Maria, Imundo, Lisa F., Kim, Susan , Rhee, Rennie L. , Stone, John H. , Sule, Sangeeta , Vitobaldi, Omar I., Warner, Ann, Byram, Kevin , Husainat, Nedaa , Kalot, Mohamad A. , Lin, Yih Chang, Springer, Jason , Turgunbaev, Marat, Villa‐Forte, Alexandra, Turner, Amy S. , Maz, Mehrdad , Conn, Doyt L , Grayson, Peter C , Merkel, Peter A , Rhee, Rennie L , Stone, John H , Sule, Sangeeta , Husainat, Nedaa M , Kalot, Mohamad A , Springer, Jason M , Turner, Amy S , Mustafa, Reem A , Chung, Sharon A. , Guyatt, Gordon , Merkel, Peter A. , Seo, Philip , Sundel, Robert P. , Warner, Ann, Dua, Anisha B. , James, Karen E.

Mayo Clinic

Arthritis Care & Research | July 8, 2021 | Volume: 73 | Issue: 8 | Pages: 1088-1105

10.1002/acr.24634 | PMID 34235880 Get It

Objective To provide evidence‐based recommendations and expert guidance for the management of antineutrophil cytoplasmic antibody–associated vasculitis (AAV), including granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA). Methods Clinical questions regarding the treatment and management of AAV were developed in the population, intervention, comparator, and outcome (PICO) format (47 for GPA/MPA, 34 for EGPA). Systematic literature reviews were conducted for each PICO question. The Grading of Recommendations Assessment, Development and Evaluation methodology was used to assess the quality of evidence and formulate recommendations. Each recommendation required ≥70% consensus among the Voting Panel. Results We present 26 recommendations and 5 ungraded position statements for GPA/MPA, and 15 recommendations and 5 ungraded position statements for EGPA. This guideline provides recommendations for remission induction and maintenance therapy as well as adjunctive treatment strategies in GPA, MPA, and EGPA. These recommendations include the use of rituximab for remission induction and maintenance in severe GPA and MPA and the use of mepolizumab in nonsevere EGPA. All recommendations are conditional due in part to the lack of multiple randomized controlled trials and/or low‐quality evidence supporting the recommendations. Conclusion This guideline presents the first recommendations endorsed by the American College of Rheumatology and the Vasculitis Foundation for the management of AAV and provides guidance to health care professionals on how to treat these diseases.
Myocarditis associated with Covid‐19 disease: A systematic review of published case reports and case series
Rathore, Sawai Singh , Rojas, Gianpier Alonzo , Sondhi, Manush , Pothuru, Suveenkrishna , Pydi, Reshma , Kancherla, Neeraj , Ahmed, Noman Khurshid, Shah, Jill, Tousif, Sohaib , Baloch, Unaiza Tariq, Wen, Qingqing, Singh, Romil

Mayo Clinic

International Journal of Clinical Practice | July 8, 2021 | Volume: 75 | Issue: 11 | Pages: No page available

10.1111/ijcp.14470 | PMID 34235815 Get It

2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis
Maz, Mehrdad , Abril, Andy , Langford, Carol A. , Gorelik, Mark , Archer, Amy M., Conn, Doyt L. , Full, Kathy A., Grayson, Peter C. , Ibarra, Maria, Imundo, Lisa F., Kim, Susan , Rhee, Rennie L. , Stone, John H. , Sule, Sangeeta , Vitobaldi, Omar I., Warner, Ann, Byram, Kevin , Dua, Anisha B. , Husainat, Nedaa , James, Karen , Kalot, Mohamad A. , Lin, Yih Chang, Springer, Jason , Turgunbaev, Marat, Villa‐Forte, Alexandra, Turner, Amy S. , Conn, Doyt L , Grayson, Peter C , Merkel, Peter A , Rhee, Rennie L , Stone, John H , Sule, Sangeeta , Husainat, Nedaa M , Kalot, Mohamad A , Springer, Jason M , Turner, Amy S , Mustafa, Reem A , Maz, Mehrdad , Dua, Anisha B , Chung, Sharon A. , Guyatt, Gordon , Merkel, Peter A. , Seo, Philip , Sundel, Robert P. , Warner, Ann

Mayo Clinic

Arthritis & Rheumatology | July 8, 2021 | Volume: 73 | Issue: 8 | Pages: 1349-1365

10.1002/art.41774 | PMID 34235884 Get It

Objective To provide evidence‐based recommendations and expert guidance for the management of giant cell arteritis (GCA) and Takayasu arteritis (TAK) as exemplars of large vessel vasculitis. Methods Clinical questions regarding diagnostic testing, treatment, and management were developed in the population, intervention, comparator, and outcome (PICO) format for GCA and TAK (27 for GCA, 27 for TAK). Systematic literature reviews were conducted for each PICO question. The Grading of Recommendations Assessment, Development and Evaluation methodology was used to rate the quality of the evidence. Recommendations were developed by the Voting Panel, comprising adult and pediatric rheumatologists and patients. Each recommendation required ≥70% consensus among the Voting Panel. Results We present 22 recommendations and 2 ungraded position statements for GCA, and 20 recommendations and 1 ungraded position statement for TAK. These recommendations and statements address clinical questions relating to the use of diagnostic testing, including imaging, treatments, and surgical interventions in GCA and TAK. Recommendations for GCA include support for the use of glucocorticoid‐sparing immunosuppressive agents and the use of imaging to identify large vessel involvement. Recommendations for TAK include the use of nonglucocorticoid immunosuppressive agents with glucocorticoids as initial therapy. There were only 2 strong recommendations; the remaining recommendations were conditional due to the low quality of evidence available for most PICO questions. Conclusion These recommendations provide guidance regarding the evaluation and management of patients with GCA and TAK, including diagnostic strategies, use of pharmacologic agents, and surgical interventions.
2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
Langford, Carol A. , Maz, Mehrdad , Abril, Andy , Gorelik, Mark , Archer, Amy M., Conn, Doyt L. , Full, Kathy A., Grayson, Peter C. , Ibarra, Maria, Imundo, Lisa F., Kim, Susan , Rhee, Rennie L. , Stone, John H. , Sule, Sangeeta , Vitobaldi, Omar I., Warner, Ann, Byram, Kevin , Dua, Anisha B. , Husainat, Nedaa , James, Karen , Kalot, Mohamad A. , Lin, Yih Chang, Springer, Jason , Turgunbaev, Marat, Villa‐Forte, Alexandra, Turner, Amy S. , Maz, Mehrdad , Conn, Doyt L , Grayson, Peter C , Merkel, Peter A , Rhee, Rennie L , Stone, John H , Sule, Sangeeta , Husainat, Nedaa M , Kalot, Mohamad A , Springer, Jason M , Turner, Amy S , Mustafa, Reem A , Dua, Anisha B , Chung, Sharon A. , Guyatt, Gordon , Merkel, Peter A. , Seo, Philip , Sundel, Robert P. , Warner, Ann

Mayo Clinic

Arthritis & Rheumatology | July 8, 2021 | Volume: 73 | Issue: 8 | Pages: 1366-1383

10.1002/art.41773 | PMID 34235894 Get It

Objective To provide evidence‐based recommendations and expert guidance for the management of antineutrophil cytoplasmic antibody–associated vasculitis (AAV), including granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA). Methods Clinical questions regarding the treatment and management of AAV were developed in the population, intervention, comparator, and outcome (PICO) format (47 for GPA/MPA, 34 for EGPA). Systematic literature reviews were conducted for each PICO question. The Grading of Recommendations Assessment, Development and Evaluation methodology was used to assess the quality of evidence and formulate recommendations. Each recommendation required ≥70% consensus among the Voting Panel. Results We present 26 recommendations and 5 ungraded position statements for GPA/MPA, and 15 recommendations and 5 ungraded position statements for EGPA. This guideline provides recommendations for remission induction and maintenance therapy as well as adjunctive treatment strategies in GPA, MPA, and EGPA. These recommendations include the use of rituximab for remission induction and maintenance in severe GPA and MPA and the use of mepolizumab in nonsevere EGPA. All recommendations are conditional due in part to the lack of multiple randomized controlled trials and/or low‐quality evidence supporting the recommendations. Conclusion This guideline presents the first recommendations endorsed by the American College of Rheumatology and the Vasculitis Foundation for the management of AAV and provides guidance to health care professionals on how to treat these diseases.
Clinical Course and Features of Seizures Associated With LGI1-Antibody Encephalitis
Smith, Kelsey M. , Liebo, Greta B. , Britton, Jeffrey W. , Liebo, Greta B , Flanagan, E P , Britton, Jeffrey W , Smith, Kelsey M , Dubey, Divyanshu , Flanagan, Eoin P.

Mayo Clinic

Neurology | July 7, 2021 | Volume: 97 | Issue: 11 | Pages: No page available

10.1212/wnl.0000000000012465 | PMID 34233939 Get It

Prescribing Aducanumab in the Face of Meager Efficacy and Real Risks
Knopman, David S. , Perlmutter, Joel S.

Mayo Clinic

Neurology | July 7, 2021 | Volume: 97 | Issue: 11 | Pages: 545-547

10.1212/wnl.0000000000012452 | PMID 34233938 Get It

COVID-19: Factors Associated with Psychol­­­ogical Distress, Fear, and Coping Strategies among Community Members Across 17 Countries
Rahman, Muhammad Aziz , Sultana, Farhana , Salehin, Masudus , Khan, Sabria Jihan , Schoenfeldt-Lecuona, C., El‐Khazragy, Nashwa , Mawali, Adhra Hilal Al, Maskari, Turkiya Saleh Al, Alharbi, Rayan Jafnan , Keblawi, Mohamad Ali , Hammoud, Majeda S. , Elaidy, Asmaa M. , Susanto, Agus Dwi , AlQurashi, Alaa , Ali, Almajdoub, Wazib, Amit, Sanluang, Cattaliya Siripattarakul, Elsori, Deena , Yasmin, Farhana , Kloub, Manal Al, Ruiz, Mara Gerbabe, Eltewacy, Nael Kamel , Oli, Natalia , Thongyu, Ratree , Almustanyir, Sami , Nitayawan, Sirirat , Al-Madhoun, Sondos , Inthong, Suwit, Ginting, Tribowo Tuahta , Rahman, Muhammad Aziz , Islam, Sheikh Mohammed Shariful , Tungpunkom, Patraporn , Alif, Sheikh Mohammad , Banik, Biswajit , Joseph, Bindu , Lam, Louisa , Watts, Mimmie Claudine , Ghozy, Sherief , Chair, Sek Ying , Chien, Wai Tong , Schönfeldt‐Lecuona, Carlos , Mahmud, Ilias , Hamza, Amr , Moni, Ahmed Suparno Bahar , Taufik, Feni Fitriani , Elsayed, Mohamed , Laham, Nahed Al , Abdelnaby, Ramy , Dweik, Rania Al , Rahman, Shaila , Alharbi, Talal Ali F. , Bahar, Tamanna , Cross, Wendy M

Mayo Clinic

No container title available | July 7, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-654989/v1 Get It

Abstract Background: The current pandemic of COVID-19 impacted the psychological wellbeing of populations globally. Objectives: We aimed to examine the extent and identify associated factors of psychological distress, fear of COVID-19, and coping.Methods: We conducted a cross-sectional study across 17 countries during Jun-2020 to Jan-2021. Levels of psychological distress (Kessler Psychological Distress Scale), fear of COVID-19 (Fear of COVID-19 Scale), and coping (Brief Resilient Coping Scale) were assessed. Results: A total of 8,559 people participated; mean age (±SD) was 33(±13) years, 64% were females and 40% self-identified as frontline workers. More than two-thirds (69%) experienced moderate-to-very high levels of psychological distress, which was 46% in Thailand and 91% in Egypt. A quarter (24%) had high levels of fear of COVID-19, which was as low as 9% in Libya and as high as 38% in Bangladesh. More than half (57%) exhibited medium to high resilient coping; the lowest prevalence (3%) was reported in Australia and the highest (72%) in Syria. Being female (AOR 1.31 [95% CIs 1.09-1.57]), perceived distress due to change of employment status (1.56 [1.29-1.90]), comorbidity with mental health conditions (3.02 [1.20-7.60]) were associated with higher levels of psychological distress and fear. Doctors had higher psychological distress (1.43 [1.04-1.97]), but low levels of fear of COVID-19 (0.55 [0.41-0.76]); nurses had medium to high resilient coping (1.30 [1.03-1.65]). Conclusions: The extent of psychological distress, fear of COVID and coping varied by country; however, some groups were more vulnerable than others. There is an urgent need to prioritise health and well-being of these people through well-designed intervention that may need to be tailored to meet country specific requirements.
Increased cell‐free fetal DNA release after apoptosis and sterile inflammation in human trophoblast cells
Kazemi, Nazanin Yeganeh , Fedyshyn, Bohdana , Yelsa, Isabel, Fedyshyn, Yaroslav , Ruano, Rodrigo , Chakraborty, Rana , Enninga, Elizabeth Ann L. , Enninga, Elizabeth Ann L , Ruano, Rodrigo , Yeganeh Kazemi, Nazanin , Markovic, Svetomir N.

Mayo Clinic

American Journal of Reproductive Immunology | July 7, 2021 | Volume: 86 | Issue: 5 | Pages: No page available

10.1111/aji.13483 | PMID 34233077 Get It

AbstractProblemCell‐free fetal DNA (cffDNA) shed from the placenta can be detected in maternal blood and increases incrementally during gestation. Concentrations are further elevated with pregnancy complications. Specific activators of cffDNA release in such complications have not been identified. Here, we use trophoblast cells from early and term placenta to examine cffDNA release following apoptosis, infection, and sterile inflammatory stress.Method of StudyHTR8/SVneo cells were used to model first‐trimester trophoblasts, and term cytotrophoblasts (CTBs) were isolated from placentae collected after uncomplicated deliveries. Trophoblasts were treated with varying concentrations of doxorubicin (DOX), lipopolysaccharide (LPS), or high‐mobility group box protein 1 (HMGB1) for 18 h. Cells or supernatants were quantified for caspase‐3/7 cleavage, pro‐inflammatory cytokine secretion, and cffDNA release.ResultsBoth HTR8/SVneo and CTBs underwent caspase‐3/7 cleavage following DOX treatment, with HTR8/SVneo cells more sensitive to apoptosis than term CTBs. Apoptotic cells released more cffDNA in a dose‐dependent manner. Treatment with LPS resulted in an increase in pro‐inflammatory IL‐6 release, particularly in term CTBs compared to early trophoblasts; however, LPS did not affect cffDNA release. Lastly, while neither cell released more TNF‐α following stimulation with HMGB1, both HTR8/SVneo and CTBs released significantly more cffDNA in the presence of HMGB1.ConclusionsThese data show that apoptosis and sterile inflammation induced by DOX and HMGB1, respectively, cause an increase in cffDNA concentrations in both first‐trimester and term trophoblasts. Understanding physiologic release of cffDNA during healthy and complicated pregnancy can identify new targets for the diagnosis and treatment of gestational complications.